Predictive Value of the Standardized Uptake Value of 18F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Assessing Axillary Lymph Node Metastasis in Different Subtypes of Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to examine the association between the maximum standardized uptake value (SUVmax) of different molecular subtypes of primary breast cancer with axillary lymph node (ALN) metastasis. Methods: The medical records of 633 patients, who underwent 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) for preoperative staging, were retrospectively reviewed. The cohort was stratified by the following molecular subtypes with immunohistochemical examination: luminal A, luminal B, human epidermal growth factor receptor 2 positive (HER2+), and triple negative. We evaluated the optimal cutoff SUVmax to predict ALN metastasis in each subtype using the receiver operating characteristic (ROC) analysis. Moreover, the risk factors for ALN metastasis were evaluated. Results: Overall, the SUVmax was positively correlated with the number of metastatic ALN (p=0.001). The mean SUVmax was higher in aggressive subtypes (4.5±0.2, 6.1±0.4, 6.5±0.5, and 7.5±0.5 in luminal A, luminal B, HER2+, and triple negative, respectively, p<0.001). Upon ROC analysis, the SUVmax of the HER2+ subtype predicted ALN metastasis most accurately, with a cutoff value of 5.5, area under the curve (AUC) of 0.708, sensitivity of 74.2%, and specificity of 64.6% (p=0.002). The triple negative subtype did not show a significant difference in SUVmax between patients with and without metastasis (p=0.13). Subtype-adjusted SUVmax, HER2 positivity, lymphovascular invasion, and T stage were significant predictors for ALN metastasis. Conclusion: The SUVmax of primary breast cancer may be an independent predictor of ALN metastasis, being the most accurate in the HER2+ subtype. As PET/CT could facilitate tailored axillary management, this approach could be considered for the initial staging and treatment planning in patients with breast cancer.
Abstract
Purpose: This study aimed to examine the association between the maximum standardized uptake value (SUVmax) of different molecular subtypes of primary breast cancer with axillary lymph node (ALN) metastasis. Methods: The medical records of 633 patients, who underwent 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET/CT) for preoperative staging, were retrospectively reviewed. The cohort was stratified by the following molecular subtypes with immunohistochemical examination: luminal A, luminal B, human epidermal growth factor receptor 2 positive (HER2+), and triple negative. We evaluated the optimal cutoff SUVmax to predict ALN metastasis in each subtype using the receiver operating characteristic (ROC) analysis. Moreover, the risk factors for ALN metastasis were evaluated. Results: Overall, the SUVmax was positively correlated with the number of metastatic ALN (p=0.001). The mean SUVmax was higher in aggressive subtypes (4.5±0.2, 6.1±0.4, 6.5±0.5, and 7.5±0.5 in luminal A, luminal B, HER2+, and triple negative, respectively, p<0.001). Upon ROC analysis, the SUVmax of the HER2+ subtype predicted ALN metastasis most accurately, with a cutoff value of 5.5, area under the curve (AUC) of 0.708, sensitivity of 74.2%, and specificity of 64.6% (p=0.002). The triple negative subtype did not show a significant difference in SUVmax between patients with and without metastasis (p=0.13). Subtype-adjusted SUVmax, HER2 positivity, lymphovascular invasion, and T stage were significant predictors for ALN metastasis. Conclusion: The SUVmax of primary breast cancer may be an independent predictor of ALN metastasis, being the most accurate in the HER2+ subtype. As PET/CT could facilitate tailored axillary management, this approach could be considered for the initial staging and treatment planning in patients with breast cancer.
참고문헌 (28)
- Jatoi I, "Surgical management of the axilla in early breast cancer", Curr Probl Surg, 55, pp.47~65 (2018)
- Donker M, "Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial", Lancet Oncol, 15, pp.1303~1310 (2014)
- Giuliano AE, "Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial", JAMA, 305, pp.569~575 (2011)
- Lavayssiere R, "Positron emission tomography(PET)and breast cancer in clinical practice", Eur J Radiol, 69, pp.50~58 (2009)
- Singh D, "Multiparametric PET", CT in oncology, 2012, pp.12, 336~344
- Fletcher JW, "Recommendations on the use of 18F-FDG PET in oncology", J Nucl Med, 49, pp.480~508 (2008)
- Veronesi U, "A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases", Ann Oncol, 18, pp.473~478 (2006)
- Heusner TA, "Diagnostic value of full-dose FDG PET", CT for axillary lymph node staging in breast cancer patients, 2009, pp.36, 1543~1550
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)
- Goldhirsch A, "Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen interantional expert consensus on the primary therapy of early breast cancer 211", Ann Oncol, 22, pp.1736~1747 (2011)
- Kim JY, "Tumour 18 F-FDG uptake on preoperative PET", CT may predict axillary lymph node metastasis in ER-positive, Eur Radiol, pp.2015, 25[DOI]
- Jung Hyun Youm, "Use of positron emission tomography-computed tomography to predict axillary metastasis in patients with triple-negative breast cancer", 대한종양외과학회지, 14(2), pp.135~141 (2018), 대한종양외과학회[DOI]
- Song BI, "Predictive Value of (18)F-FDG PET", CT for Axillary lymph node metastasis in invasive ductal breast cancer, 2017, pp.24, 2174~2181
- Malcolm D. Mattes, "Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry", Journal of Breast Cancer, 18(2), pp.143~148 (2015), 한국유방암학회
- Zhu X, "Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China", Breast Cancer Res Treat, 147, pp.551~555 (2014)
- Holm-Rasmussen EV, "Reduced risk of axillary lymphatic spread in triple-negative breast cancer", Breast Cancer Res Treat, 149, pp.229~236 (2015)
- fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?, "Breast", 2013, 39~43
- Basu S, "Comparison of triple-negative and estrogen receptor-positive", progesterone receptor-positive, positron emission tomography imaging parameters: a potentially useful method for disease characterization, pp.Cancer, 2008[DOI]
- Jung NY, "The value of primary tumor (18)F-FDG uptake on preoperative PET", CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis, 2016, pp.23, 712~717
- Ueda S, "Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography", computed tomography fusion imaging (18F-FDG PET, Jpn J Clin Oncol, pp.2008, 38[DOI]
- Specht JM, "Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer", Clin Cancer Res, 16, pp.2803~2810 (2010)
- Koo HR, "18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes", Eur Radiol, 24, pp.610~618 (2014)
- Lovrics PJ, "A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer", Ann Surg Oncol, 11, pp.846~853 (2004)
- Ahn JH, "The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer", Acta Radiol, 51, pp.859~865 (2010)
- Woo Young Sun, "Prediction of Axillary Nodal Status according to the Axillary Lymph Node to Primary Breast Tumor Maximum Standardized Uptake Value Ratio on 18F-fluorodeoxyglucose Positron Emission Tomography", Computed Tomography, 2016, pp.4(2), 92~99[DOI]
- Carkaci S, "Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?", Acad Radiol, 19, pp.535~541 (2012)
- Crippa F, "FDG-PET for axillary lymph node staging in primary breast cancer", Eur J Nucl Med Mol Imaging, 31(Suppl 1), pp.S97~S102 (2004)
- Ahn SG, "Standardized uptake value of (1)(8)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden", Breast Cancer Res, 16, pp.502~ (2014)